posaconazole oral suspension  (Hunan Kelun Pharmaceutical Co Ltd)

Journal: Journal of Antimicrobial Chemotherapy

Article Title: Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis

doi: 10.1093/jac/dkaf355

Figure Lengend Snippet: PD of olorofim and posaconazole alone and in combination in a murine model of invasive pulmonary aspergillosis with NIH4215 (posaconazole MIC = 0.125 mg/L; olorofim MIC = 0.03 mg/L) as the challenge strain. Symbols and error bars represent mean and standard error, respectively, of the GM index in the absence of antifungal agent (a), two olorofim monotherapy regimens (b and c), one posaconazole monotherapy regimen (d) and two combination regimens with both olorofim and posaconazole (e and f).

Article Snippet: For in vivo murine studies, posaconazole oral suspension (Noxafil, MSD, Merck, UK) was stored at 4°C and diluted in 20% HPBCD (4 g HPBCD in 20 mL water) as necessary.

Techniques:

Journal: Journal of Antimicrobial Chemotherapy

Article Title: Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis

doi: 10.1093/jac/dkaf355

Figure Lengend Snippet: PD of olorofim and posaconazole alone and in combination in a murine model of invasive pulmonary aspergillosis with 11628 (posaconazole MIC = 0.5 mg/L; olorofim MIC = 0.03 mg/L) as the challenge strain. Symbols and error bars represent mean and standard error, respectively, of the GM index in the absence of antifungal agent (a), two olorofim monotherapy regimens (b and c), one posaconazole monotherapy regimen (d) and two combination regimens with both olorofim and posaconazole (e and f).

Article Snippet: For in vivo murine studies, posaconazole oral suspension (Noxafil, MSD, Merck, UK) was stored at 4°C and diluted in 20% HPBCD (4 g HPBCD in 20 mL water) as necessary.

Techniques:

Journal: Journal of Antimicrobial Chemotherapy

Article Title: Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis

doi: 10.1093/jac/dkaf355

Figure Lengend Snippet: Experimental time-concentration profiles from the PK arms of the murine model for (a) posaconazole 5 mg/kg q24h p.o., (b) posaconazole 10 mg/kg q24h p.o., (c) posaconazole 15 mg/kg q24h p.o., (d) olorofim 4 mg/kg q8h i.v., (e) olorofim 8 mg/kg q8h i.v. and (f) olorofim 12 mg/kg q8h i.v. Solid lines indicate the predicted time-concentration profile using the fitted PK-PD model using the mean PK parameters. Crosses indicate measured plasma concentrations from mice receiving the relevant regimen.

Article Snippet: For in vivo murine studies, posaconazole oral suspension (Noxafil, MSD, Merck, UK) was stored at 4°C and diluted in 20% HPBCD (4 g HPBCD in 20 mL water) as necessary.

Techniques: Concentration Assay, Clinical Proteomics

Journal: Journal of Antimicrobial Chemotherapy

Article Title: Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis

doi: 10.1093/jac/dkaf355

Figure Lengend Snippet: Observed-versus-predicted plots demonstrating population fit for the fitted PK-PD model using mean parameter estimates for NIH4215 (a–c) and 11628 (d–f) and for model performance by posaconazole plasma concentration (a and d), olorofim plasma concentration(b and e) and GM index (c and f). GI = GM index.

Article Snippet: For in vivo murine studies, posaconazole oral suspension (Noxafil, MSD, Merck, UK) was stored at 4°C and diluted in 20% HPBCD (4 g HPBCD in 20 mL water) as necessary.

Techniques: Clinical Proteomics, Concentration Assay

Journal: Journal of Antimicrobial Chemotherapy

Article Title: Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis

doi: 10.1093/jac/dkaf355

Figure Lengend Snippet: Simulation output using the NIH4215 strain PK-PD model with no treatment (a), posaconazole 400 mg q24h p.o. (b), olorofim 90 mg q12h p.o. (c) and both in combination (d). The solid line is the median GM trajectory. Dashed lines indicate 5th and 95th centiles. While the interaction is antagonistic, there is a greater effect with the combination than with either monotherapy.

Article Snippet: For in vivo murine studies, posaconazole oral suspension (Noxafil, MSD, Merck, UK) was stored at 4°C and diluted in 20% HPBCD (4 g HPBCD in 20 mL water) as necessary.

Techniques:

Journal: Journal of Antimicrobial Chemotherapy

Article Title: Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis

doi: 10.1093/jac/dkaf355

Figure Lengend Snippet: Simulation output using the 11628 strain PK-PD model with no treatment (a), posaconazole 400 mg q24h p.o. (b), olorofim 90 mg q12h p.o. (c) and both in combination (d).

Article Snippet: For in vivo murine studies, posaconazole oral suspension (Noxafil, MSD, Merck, UK) was stored at 4°C and diluted in 20% HPBCD (4 g HPBCD in 20 mL water) as necessary.

Techniques:

Journal: Journal of Veterinary Internal Medicine

Article Title: Treatment of Disseminated Aspergillosis with Posaconazole in 10 Dogs

doi: 10.1111/jvim.13795

Figure Lengend Snippet: Serial serum Aspergillus galactomannan antigen assay ( GMA ) index results for 2 dogs while receiving posaconazole treatment; data set 1 (diamonds) and data set 2 (squares). GMA index results ≥1.5 were considered positive. Missing data points not included.

Article Snippet: Noxafil (Posaconazole) oral suspension 40 mg/mL, Merck & Co., Inc., Whitehouse Station, NJ

Techniques: Antigen Assay